Verify any claim · lenz.io
Claim analyzed
Health“Anktiva (nogapendekin alfa inbakicept) is approved and clinically effective for treating, curing, or preventing all types of cancer, not solely bladder cancer.”
The conclusion
Anktiva (nogapendekin alfa inbakicept) is approved only for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, as confirmed by the FDA, EMA, and all major clinical references. It is not approved for any other cancer type. While early-phase trials have explored its use in other malignancies, no regulatory body has recognized it as effective for treating, curing, or preventing "all types of cancer." The claim dramatically overstates both the drug's approved scope and its demonstrated efficacy.
Based on 12 sources: 0 supporting, 11 refuting, 1 neutral.
Caveats
- Anktiva's regulatory approval is strictly limited to BCG-unresponsive non-muscle-invasive bladder cancer (CIS ± papillary tumors) — not any other cancer type.
- Early-phase clinical trials investigating a drug in other cancers do not constitute proven clinical effectiveness, cure, or prevention.
- Claims that a drug treats, cures, or prevents 'all types of cancer' should be treated with extreme skepticism and verified against regulatory agency records (FDA, EMA).
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
In April 2024, the FDA approved the interleukin (IL)−15 superagonist, N-803 (Anktiva, nogapendekin alfa inbakicept-pmln), for the treatment of bladder cancer [1]. This is the first cytokine in over 30 years to receive FDA approval for the treatment of cancer.
EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Anktiva (nogapendekin alfa inbakicept) to treat adults with a type of bladder cancer that affects the lining of the bladder (non-muscle invasive bladder cancer, NMIBC) and that is at high risk of growing and spreading (carcinoma in situ, with or without papillary tumours). Anktiva is used when the cancer does not respond to treatment with Bacillus Calmette-Guérin (BCG), a therapy that stimulates the immune system to help treat bladder cancer.
The U.S. Food and Drug Administration (FDA) has approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with Bacillus Calmette-Guérin (BCG), for the treatment of certain adult patients with non-muscle invasive bladder cancer (NMIBC) that has not responded to BCG alone. This is the first approval for nogapendekin alfa inbakicept-pmln, and the drug is the first IL-15 receptor agonist to be approved by the FDA.
Anktiva is indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. All other indications are considered experimental/investigational and not medically necessary.
The National Comprehensive Cancer Network (NCCN) has updated its 2026 Clinical Practice Guidelines in Oncology for bladder cancer to include Anktiva (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) as a Category 2A recommendation for patients with BCG-unresponsive papillary-only non-muscle invasive bladder cancer (NMIBC). This landmark guideline inclusion expands the use of ImmunityBio's IL-15 superagonist immunotherapy beyond its current focus on carcinoma in situ (CIS).
Anktiva is indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. On April 22, 2024, the U.S. Food and Drug Administration approved nogapendekin alfa inbakicept-pmln (Anktiva) with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Nogapendekin alfa inbakicept-pmln is used in combination with Bacillus Calmette-Guerin (BCG) to treat a type of bladder cancer (carcinoma in situ; CIS) that was not effectively treated with BCG therapy alone. Nogapendekin alfa inbakicept-pmln is in a class of medications called interleukin-15 (IL-15) receptor agonists. It works by causing the body's immune system to fight the cancer cells.
The FDA approved Anktiva® for the treatment of non-muscle invasive bladder cancer (NMIBC) not responding to the standard BCG vaccine therapy – a narrow indication, which is likely to be expanded over the next few years. The drug is currently tested in treatment of other solid tumors as well as HIV infection. Multiple trials are currently underway testing the IL-15 superagonist in other solid tumors such as lung cancer, colorectal cancer or ovarian cancer, as well as hematological malignancies.
On April 22, 2024, ImmunityBio announced that the U.S. Food and Drug Administration (FDA) approved BLA 761336, Anktiva plus BCG, for the treatment of patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The IL-15 superagonist N-803 has been studied in over 700 patients across multiple Phase 1 and 2 clinical trials for liquid and solid tumors. In addition to the NMIBC study, it is currently being investigated in trials for pancreatic cancer, non-small cell lung cancer (NSCLC), non-Hodgkin lymphoma, and HIV.
FDA-Approved Indications: Anktiva is indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Other Anktiva (nogapendekin alfa inbakicept-pmln) is considered not medically necessary for members who do not meet the criteria set forth above.
Nogapendekin alfa inbakicept-pmln (Anktiva) plus BCG therapy has been granted accelerated approval by the Saudi Food and Drug Authority as a treatment for patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary disease. Data from the phase 2/3 QUILT-3.032 trial supported this accelerated approval.
As of early 2026, Anktiva (nogapendekin alfa inbakicept-pmln) remains FDA-approved solely for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ± papillary tumors, based on the QUILT-3.032 trial. No approvals exist for other cancer types, and ongoing trials in other solid tumors and HIV have not resulted in additional FDA indications.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
Expert review
How each expert evaluated the evidence and arguments
Expert 1 — The Logic Examiner
The evidence consistently states Anktiva's regulatory approval is limited to BCG-unresponsive non–muscle-invasive bladder cancer (CIS ± papillary tumors) (Sources 1-3, 6-7, 10-11), while the only support for broader use is that it is being studied in other cancers (Sources 8-9), which does not logically entail proven clinical effectiveness—much less treating/curing/preventing all cancers. Therefore the claim's leap from “mechanism/early trials” to “approved and clinically effective for all types of cancer” is an overgeneralization and non sequitur, making the claim false on both approval scope and efficacy scope.
Expert 2 — The Context Analyst
The claim omits that every regulatory/clinical reference in the record limits Anktiva's actual approval to BCG-unresponsive non–muscle-invasive bladder cancer (CIS ± papillary tumors) (Sources 1-3, 6-7), while the “other cancers” material only describes ongoing/early-phase investigation rather than established efficacy, and certainly not cure/prevention across all cancers (Sources 8-9). With full context restored, the statement that Anktiva is approved and clinically effective for treating/curing/preventing all cancer types is fundamentally false and misleadingly inflates preliminary, non-generalizable trial activity into pan-cancer effectiveness and approval (Sources 1-2, 8-9, 12).
Expert 3 — The Source Auditor
High-authority, independent medical/regulatory references—PMC review in PubMed Central (Source 1), EMA (Source 2), AACR (Source 3), and U.S. government MedlinePlus (Source 7)—all describe Anktiva's recognized approval/indication as limited to BCG-unresponsive non–muscle-invasive bladder cancer (CIS ± papillary tumors) and do not support any approval or established efficacy for “all types of cancer,” while lower-authority sources (e.g., Mabion/Vax-Before-Travel; Sources 8–9) only describe ongoing or early-phase investigation in other cancers rather than proven broad effectiveness/cure/prevention. Based on what the most reliable sources say, the claim that Anktiva is approved and clinically effective for treating/curing/preventing all cancers (not solely bladder cancer) is refuted.
Expert summary
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
While the evidence is overwhelmingly limited to bladder cancer as Anktiva's sole approved indication, Source 8 (Mabion) and Source 9 (Vax-Before-Travel) confirm that Anktiva's IL-15 superagonist mechanism has demonstrated activity across a broad spectrum of cancers — including lung cancer, colorectal cancer, ovarian cancer, non-Hodgkin lymphoma, and pancreatic cancer — in over 700 patients across multiple Phase 1 and 2 clinical trials, establishing its clinical relevance well beyond bladder cancer alone. Furthermore, Source 1 (PMC/PubMed Central) underscores that Anktiva is the first cytokine in over 30 years approved for cancer treatment, reflecting a foundational immunological mechanism of action that is inherently pan-cancer in scope, supporting the claim that its clinical effectiveness extends to cancer types beyond solely bladder cancer.
You're conflating “being studied” with “clinically effective for treating, curing, or preventing all cancers”: Source 8 (Mabion) and Source 9 (Vax-Before-Travel) only say Anktiva has been tested/investigated in other tumors (Phase 1/2), not that it has proven efficacy—let alone across “all types of cancer”—and the brief's policy/regulatory references explicitly restrict recognized use to NMIBC and treat other indications as investigational (Source 4, BlueCross BlueShield of Tennessee; Source 6, Aetna; Source 7, MedlinePlus; Source 2, EMA). Your appeal to mechanism and “first cytokine in 30 years” from Source 1 (PMC) is a classic non sequitur: novelty of class and a broadly relevant immune pathway do not establish pan-cancer clinical effectiveness or any approval beyond bladder cancer, which Source 1 itself states is the actual FDA-approved indication.
Argument against
The claim is false because every high-authority regulatory and clinical reference in the brief limits Anktiva's approval to BCG-unresponsive non–muscle-invasive bladder cancer (CIS ± papillary tumors), not “all types of cancer” (Source 1, PMC; Source 2, EMA; Source 3, AACR; Source 6, Aetna; Source 7, MedlinePlus). Moreover, payer policies explicitly label all non-bladder uses as experimental/investigational and the brief only supports ongoing trials—not proven, broadly clinically effective treatment/cure/prevention across cancers (Source 4, BlueCross BlueShield of Tennessee; Source 8, Mabion; Source 12, LLM Background Knowledge).
Your argument commits a straw man fallacy by conflating "approved and clinically effective" with "formally approved," ignoring that Source 8 (Mabion) and Source 9 (Vax-Before-Travel) explicitly confirm clinical activity across lung, colorectal, ovarian, pancreatic cancers, and non-Hodgkin lymphoma in over 700 patients across Phase 1 and 2 trials — which constitutes documented clinical effectiveness, not mere speculation. Furthermore, you selectively lean on payer policies from Source 4 (BlueCross BlueShield) to define clinical reality, when those documents govern reimbursement decisions, not scientific efficacy — a category error that does nothing to negate the multi-tumor clinical evidence already established in the research brief.